Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Down 2.4% – Time to Sell?

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) traded down 2.4% during trading on Tuesday . The stock traded as low as $6.49 and last traded at $6.56. 939,641 shares traded hands during trading, a decline of 84% from the average session volume of 5,785,825 shares. The stock had previously closed at $6.72.

Wall Street Analyst Weigh In

RXRX has been the subject of several recent analyst reports. Needham & Company LLC decreased their target price on shares of Recursion Pharmaceuticals from $16.00 to $11.00 and set a “buy” rating for the company in a report on Wednesday, September 4th. Jefferies Financial Group decreased their price objective on shares of Recursion Pharmaceuticals from $8.00 to $6.00 and set a “hold” rating for the company in a report on Tuesday, September 3rd. Leerink Partners reduced their target price on Recursion Pharmaceuticals from $9.00 to $8.00 and set a “market perform” rating for the company in a report on Tuesday, September 3rd. Finally, KeyCorp reduced their price target on shares of Recursion Pharmaceuticals from $16.00 to $12.00 and set an “overweight” rating for the company in a research note on Thursday, July 11th. Four investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $9.40.

Recursion Pharmaceuticals Trading Down 6.6 %

The company has a market capitalization of $1.56 billion, a P/E ratio of -4.22 and a beta of 0.80. The company has a debt-to-equity ratio of 0.04, a quick ratio of 6.07 and a current ratio of 6.07. The stock has a fifty day moving average of $6.70 and a 200 day moving average of $7.82.

Recursion Pharmaceuticals (NASDAQ:RXRX) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.05). The company had revenue of $14.42 million during the quarter, compared to the consensus estimate of $11.96 million. Recursion Pharmaceuticals had a negative return on equity of 79.47% and a negative net margin of 755.37%. The firm’s quarterly revenue was up 30.9% compared to the same quarter last year. During the same period last year, the business earned ($0.38) EPS. As a group, equities research analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.58 EPS for the current fiscal year.

Insider Buying and Selling

In other Recursion Pharmaceuticals news, CFO Michael Secora sold 15,000 shares of the stock in a transaction that occurred on Tuesday, October 8th. The shares were sold at an average price of $6.32, for a total transaction of $94,800.00. Following the completion of the sale, the chief financial officer now directly owns 1,426,506 shares of the company’s stock, valued at $9,015,517.92. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In other news, CFO Michael Secora sold 15,000 shares of Recursion Pharmaceuticals stock in a transaction dated Tuesday, October 8th. The stock was sold at an average price of $6.32, for a total value of $94,800.00. Following the sale, the chief financial officer now directly owns 1,426,506 shares of the company’s stock, valued at approximately $9,015,517.92. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Blake Borgeson sold 11,447 shares of the business’s stock in a transaction dated Tuesday, July 23rd. The stock was sold at an average price of $8.48, for a total value of $97,070.56. Following the completion of the sale, the director now owns 7,155,663 shares in the company, valued at $60,680,022.24. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 201,682 shares of company stock valued at $1,353,652. Corporate insiders own 15.75% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Benjamin F. Edwards & Company Inc. bought a new position in Recursion Pharmaceuticals during the first quarter valued at $26,000. GAMMA Investing LLC lifted its holdings in shares of Recursion Pharmaceuticals by 1,588.4% in the 2nd quarter. GAMMA Investing LLC now owns 6,416 shares of the company’s stock valued at $48,000 after acquiring an additional 6,036 shares during the last quarter. Amalgamated Bank grew its position in Recursion Pharmaceuticals by 52.4% in the second quarter. Amalgamated Bank now owns 7,152 shares of the company’s stock worth $54,000 after acquiring an additional 2,459 shares in the last quarter. San Luis Wealth Advisors LLC bought a new stake in Recursion Pharmaceuticals during the third quarter worth approximately $69,000. Finally, Vontobel Holding Ltd. purchased a new stake in Recursion Pharmaceuticals during the third quarter valued at approximately $70,000. 89.06% of the stock is owned by hedge funds and other institutional investors.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.